Back to top
more

West Pharmaceutical Services (WST)

(Real Time Quote from BATS)

$330.35 USD

330.35
309,963

+15.58 (4.95%)

Updated Nov 5, 2024 12:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 250)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Nalak Das headshot

Wall Street is Northbound Defying All Concerns: 5 Top Picks

by Nalak Das

A new bull market that was developed last quarter exiting the coronavirus-induced short bear market, is raging forward in the third quarter too.

IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise

by Zacks Equity Research

IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.

Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract

by Zacks Equity Research

Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.

Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines

by Zacks Equity Research

Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.

Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises

by Zacks Equity Research

Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.

Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates

by Zacks Equity Research

Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.

Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y

by Zacks Equity Research

Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.

Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Stryker's (SYK) second-quarter earnings reflect weak segmental performance.

OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

OPKO Health's (OPK) second-quarter results benefit from increase in RAYALDEE prescriptions.

Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline

by Zacks Equity Research

Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.

Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise

by Zacks Equity Research

Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.

West Pharmaceutical's Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in West Pharmaceutical Services.

Boston Scientific (BSX) Q2 Earnings Top, Margins Decline

by Zacks Equity Research

This time too Boston Scientific (BSX) refrains from providing any update on the full-year guidance.

Amedisys (AMED) Earnings and Revenues Beat Estimates in Q2

by Zacks Equity Research

Amedisys' (AMED) second-quarter results reflect impressive performance by the Hospice division despite pandemic-led challenges.

Omnicell (OMCL) Q2 Earnings Lag Estimates, Margins Down

by Zacks Equity Research

Omnicell's (OMCL) second-quarter revenues suffered due to slowdown in hospital purchasing decisions and product bookings owing to pandemic-led business disruptions.

West Pharmaceutical Services (WST) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

West Pharmaceutical (WST) delivered earnings and revenue surprises of 37.36% and 6.89%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Why West Pharmaceutical (WST) Could Beat Earnings Estimates Again

by Zacks Equity Research

West Pharmaceutical (WST) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Sweta Killa headshot

S&P 500 Turns Positive for 2020: 10 Top Stocks in ETF

by Sweta Killa

The S&P 500 index turns positive for 2020. We have highlighted 10 stocks that are leading the way in the ETF.

Here's Why You Should Retain DexCom (DXCM) Stock For Now

by Zacks Equity Research

DexCom (DXCM) continues to gain traction from strong international presence and robust product portfolio.

    Luminex (LMNX) Receives EUA for New COVID-19 Antibody Test

    by Zacks Equity Research

    Luminex (LMNX) receives EUA for its xMAP SARS-CoV-2 Multi-Antigen IgG Assay, which can be used to rapidly detect the presence of antibodies in people affected by the virus causing COVID-19.

      Is West Pharmaceutical Services (WST) Stock Outpacing Its Medical Peers This Year?

      by Zacks Equity Research

      Is (WST) Outperforming Other Medical Stocks This Year?

      Patterson Cos. (PDCO) Hits Fresh High: Is There Still Room to Run?

      by Zacks Equity Research

      Patterson Cos. (PDCO) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

      Zacks.com featured highlights include: Boise Cascade, Lakeland Industries, NextEra Energy, FormFactor and West Pharmaceutical Services

      by Zacks Equity Research

      Zacks.com featured highlights include: Boise Cascade, Lakeland Industries, NextEra Energy, FormFactor and West Pharmaceutical Services

      Abiomed Gets FDA Nod for Data Streaming Via Impella Connect

      by Zacks Equity Research

      Abiomed's (ABMD) announcement of the FDA approval of one-way digital data streaming from the Impella Connect interface can boost patient outcomes further.

      5 Low Leverage Stocks to Secure Your Portfolio in 2H2020

      by Zacks Equity Research

      To safeguard one's portfolio from notable losses, the real challenge for an investor is determining whether the organization's debt level is sustainable.